16.01.2013 Views

cGMP manufacturing for (pre-)clinical trials ... - Eurogentec

cGMP manufacturing for (pre-)clinical trials ... - Eurogentec

cGMP manufacturing for (pre-)clinical trials ... - Eurogentec

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Therapeutic<br />

Oligonucleotides<br />

<strong>cGMP</strong> <strong>manufacturing</strong><br />

<strong>for</strong> (<strong>pre</strong>-)<strong>clinical</strong> <strong>trials</strong>


New from <strong>Eurogentec</strong>: Therapeutic Oligonucleotides<br />

Oligonucleotide-based drugs are now rapidly establishing themselves as important tools<br />

in both research and treatment of genetic disorders. Recent knowledge about RNA<br />

interference has boosted interest in this field. An increasing number of oligonucleotidebased<br />

pharmaceutical products are now in in various stages of <strong>clinical</strong> development <strong>for</strong><br />

the treatment of life-threatening so far incurable diseases. As a result, the production of<br />

synthetic oligonucleotides has become increasingly important, with applications in<br />

antisense-, aptamer-, immunostimulatory CpG molecule- and RNAi-related therapeutics.<br />

In response to this development, <strong>Eurogentec</strong> Biologics, leader in GMP <strong>manufacturing</strong> of<br />

biopharmaceuticals and <strong>Eurogentec</strong> Genomics, expert in oligonucleotide synthesis and<br />

purification, have joint <strong>for</strong>ces to offer a new service: <strong>cGMP</strong> <strong>manufacturing</strong> of<br />

oligonucleotides <strong>for</strong> therapeutic use.<br />

Global solution in one company: from target discovery to<br />

<strong>clinical</strong> <strong>trials</strong><br />

<strong>Eurogentec</strong>’s approach in building a new team with synergistic expertise has resulted in a<br />

unique service that helps minimize the risks attached to outsourcing <strong>manufacturing</strong> in<br />

oligonucleotide drug development. By offering small-scale non-<strong>cGMP</strong> oligonucleotides <strong>for</strong><br />

target discovery and <strong>pre</strong>-<strong>clinical</strong> toxicology studies (typically less than 1 gram) and<br />

mid-scale <strong>cGMP</strong> oligonucleotides <strong>for</strong> human <strong>clinical</strong> <strong>trials</strong> (up to 10 gram), we deliver an<br />

integrated <strong>manufacturing</strong> program that enables seamless transition from target discovery<br />

and <strong>pre</strong>-<strong>clinical</strong> studies to <strong>clinical</strong> <strong>trials</strong>.<br />

� Expertise to produce complex and modified oligonucleotides (siRNA, LNA, 2’OMe…).<br />

� Expert advice on oligonucleotide design and delivery systems.<br />

� Dedicated <strong>cGMP</strong> facilities <strong>for</strong> RNA and DNA production.<br />

� Capacities from milligrams to 10 gram and beyond.<br />

� Lab and industrial scale purification systems.<br />

� Ultra filtration and freeze drying.<br />

� Clean rooms <strong>for</strong> purification and isolation.<br />

� Full range of QC release testing specific to oligonucleotides.<br />

� Biodistribution and design services<br />

About <strong>Eurogentec</strong> Biologics<br />

The Biologics Division of <strong>Eurogentec</strong> is a leading contract manufacturer of<br />

biopharmaceuticals <strong>for</strong> <strong>clinical</strong> <strong>trials</strong> and market supply. We offer cell banking, process<br />

and analytical development and production of bacterial vaccines, recombinant or natural<br />

proteins and plasmid DNA according to current GMPs of European and US regulatory<br />

authorities. To date, <strong>Eurogentec</strong> Biologics has manufactured more than 270 <strong>clinical</strong><br />

batches of over 60 different drug substances. For the past 12 years, we have successfully<br />

served small start-ups and large pharmaceutical companies in Europe and North America<br />

and are committed to expand our services worldwide.<br />

About <strong>Eurogentec</strong> Genomics<br />

With over 20 years of experience in oligonucleotide synthesis, <strong>Eurogentec</strong> has grown into<br />

a leading provider <strong>for</strong> genomic research as well as DNA- and RNA-based diagnostic<br />

testing. <strong>Eurogentec</strong> maintains a proven track record of <strong>manufacturing</strong> the widest range<br />

of oligonucleotide modifications in the industry. Being a healthy and professional<br />

company, we are able to offer reliable, flexible and cost-effective solutions <strong>for</strong> research,<br />

R&D and <strong>clinical</strong> use of oligonucleotides.


<strong>Eurogentec</strong>, your oligonucleotide partner of<br />

choice in drug development.<br />

For inquiries, please contact the EUROGENTEC Diagnostic Oligonucleotide Team:<br />

IND-THERAPOLIGO-0507-V3<br />

Customers in Europe and USA:<br />

Tel.: + 32 (0)4 372 7437 (Muriel Craynest, Ph.D.)<br />

Tel.: + 32 (0)4 372 7635 (Peter Haima, Ph.D.)<br />

therapeutic.oligo@eurogentec.com<br />

Customers in Asia:<br />

Tel.: + 81 (0)76 411 02 77 (Japan)<br />

info@n-egt.com<br />

Tel.: + 65 (0)6778 9388 (Singapore)<br />

therapeutic.oligo@eurogentec.com

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!